Craig Hale, general counsel for XanGo, noted the company is working to resolve the situation with FDA. “XanGo recently received a warning letter from the FDA related to some mangosteen materials it obtained through a third-party publishing company,” Hale said. “While it is unclear from the letter, it appears that the FDA believes that it ordered the literature directly from XanGo and that these materials are company-produced literature. This is not the case, and we believe this fact will be important in resolving the issue. … From its beginnings, XanGo has been committed to complying to the federal regulations that govern both the natural products and direct sales industries. XanGo does not publish nor endorse any literature that makes health claims. Further, XanGo does not condone the use of noncompliant literature by its distributors and makes every effort to educate distributors on the difference between compliant and non-compliant literature. XanGo is confident that we will shortly reach an appropriate resolution.”
Natural Products Industry Insider – XanGo Addressing FDA Health Claim Concerns
